• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MaxCyte, Inc. - Common Stock (NQ:MXCT)

    1.540 -0.080 (-4.94%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about MaxCyte, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Participate in Baird Global Healthcare Conference
    From MaxCyte, Inc
    Via GlobeNewswire
    Recap: MaxCyte Q1 Earnings
     
    Via Benzinga
    Looking Into MaxCyte's Return On Capital Employed
     
    Via Benzinga
    MaxCyte's Earnings: A Preview
     
    Via Benzinga
    MaxCyte Earnings Perspective: Return On Capital Employed
     
    Via Benzinga
    MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
    Prime Medicine to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance their innovative Prime Editing technology and develop a new class of one-time, potentially curative... 
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
    MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support Vittoria’s Senza5™ technology to enhance efficacy and improve clinical utility of T-cell therapies. 
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License with Lyell Immunopharma
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Participate in Upcoming Investor Conferences
    From MaxCyte, Inc
    Via GlobeNewswire
    Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales. 
    Via Benzinga
    Disney, Sonos, Desktop Metal And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Sonos, Inc. (NASDAQ: SONO) shares dipped 25.2% to $15.82 in pre-market... 
    Via Benzinga
    MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
    Walking Fish to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases 
    From MaxCyte, Inc
    Via GlobeNewswire
    7 Small-Cap Biotech Stocks with Massive Potential
    Although small-cap biotech stocks present high risks, if they hit one out of the park, the rewards can be astronomical. 
    Via InvestorPlace
    MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
    From MaxCyte, Inc
    Via GlobeNewswire
    Around $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
    The Dow Jones closed higher by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or ... 
    Via Benzinga
    MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
    31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue 
    From MaxCyte, Inc
    Via GlobeNewswire
    Earnings Scheduled For March 15, 2023
    Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. 
    Via Benzinga
    MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
    MaxCyte’s Scientific Advisory Board will provide guidance to shape the technical direction of the company’s innovation initiatives focused on the discovery, development and manufacturing of... 
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023
    For those that want to take a journey on the wild side of the market, these penny stocks may offer significant upside rewards. 
    Via InvestorPlace
    MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
    MaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapies 
    From MaxCyte, Inc
    Via GlobeNewswire
    7 Hot Stocks to Book Profits In Before 2023
    With major macroeconomic headwinds appearing on the horizon, it’s time for investors to consider the hot stocks to book profits in. 
    Via InvestorPlace
    MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
    Curamys to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to help advance its cell fusion technology. 
    From MaxCyte, Inc
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.